Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Metabolic pathways
• Cancer biology

Background:

• Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), characterized by significant biological heterogeneity.
• Traditional classification relies on genetic and transcriptomic features, but metabolic subtypes are emerging as key therapeutic targets.
• Current chemoimmunotherapy affects tumor metabolism broadly, presenting an opportunity for more targeted approaches.

Purpose of the Study:

• To review how standard therapies impact DLBCL metabolism and explore metabolic heterogeneity.
• To evaluate targeted metabolic therapies and their potential in specific DLBCL subsets.
• To discuss novel combination strategies involving metabolic inhibitors, immunotherapy, and cellular therapies.

Main Methods:

• Literature review of existing research on DLBCL metabolism and targeted therapies.
• Analysis of metabolic dependencies in different DLBCL subtypes.
• Examination of metabolic interactions between tumor cells and immune effectors (e.g., CAR T cells).

Main Results:

• Novel inhibitors targeting glucose, amino acid, lipid, and mitochondrial metabolism show selective cytotoxicity in defined lymphoma subsets.
• Standard therapies exploit DLBCL metabolic dependencies, but lack precision.
• Metabolic interactions are crucial for the efficacy of immunotherapies like CAR T cells.

Conclusions:

• Metabolic subtypes represent novel vulnerabilities in DLBCL.
• Targeted metabolic therapies offer a promising strategy to enhance treatment efficacy.
• Translational research is essential to validate subtypes, identify biomarkers, and develop rational combination therapies for improved patient outcomes.